Rhythm Biosciences appoints innovation executive to board

Latest News

Rhythm Biosciences (ASX:RHY) has announced the appointment of Eduardo Vom as a new non-executive director.

The company is developing its ColoSTAT non-invasive blood screening diagnostic test for colorectal cancer.

Mr Vom is a co-founder and executive director of Planet Innovation, a technology development and commercialisation company, and three times winner of The Australian Financial Review’s Most Innovative Companies. He has a long association with the company as a shareholder and through his involvement as an advisor during the company’s inception.

He has over twenty years of experience in technology development and commercialisation in the biotechnology industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies.

According to the chairman Rhythm Biosciences, Otto Buttula, “We are pleased to secure a non-executive director of Eduardo’s calibre to the Board. His proven capabilities in delivering results coupled with his intimate knowledge of Rhythm’s technology and the Company’s origins is an important addition. I welcome Eduardo to Rhythm and the Board and look forward to working with him to advance our ambition to become a globally significant developer of mass market screening technology for the early detection of colorectal cancer.”

Mr Vom added, “I look forward to joining Rhythm at a pivotal moment in the Company’s development. I have been an investor from the start, following closely the significant advancements made since the Company began commercialising the technology originally developed by the CSIRO.

"We have a massive opportunity here with global relevance, not only to save lives, but to influence the overall quality of people’s lives. That is something I want to be a part of.”